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Abstract
Background: Pertussis, or “whooping cough,” is an acute, contagious pulmonary
disease that, despite being vaccine-preventable, has become an increasingly
widespread problem in the United States. As a result, the Advisory Committee
on Immunization Practices and American College of Obstetricians and
Gynecologists updated recommendations stating clinicians should give a Tdap
dose during every pregnancy, preferably at 27e36 weeks. Despite this
recommendation, reported Tdap vaccine receipt rates during pregnancy vary from
16e61%, and previous studies have shown that clinician recommendation and
vaccine administration are strongly associated with vaccine uptake among
pregnant women.
Methods: Our aim was to inform new strategies to increase uptake of the Tdap
vaccine among pregnant women and, ultimately, reduce pertussis-related
morbidity and mortality in infants. We conducted interviews with a sample of 24
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ob-gyns. We subsequently performed grounded theory analyses of transcripts using
deductive and inductive coding strategies followed by intercoder reliability
assessment.
Results: All physicians interviewed were familiar with the most recent
recommendation of giving the Tdap vaccine during the third trimester of every
pregnancy, and the majority of physicians stated that they felt that the vaccine
was important and eﬀective due to the transfer of pertussis antibodies from the
mother to the fetus. Most physicians indicated that they recommended the
vaccine to patients during pregnancy, but not all reported administering it on site
because it was not stocked at their practice. Implementation challenges for
physicians included insurance reimbursement and other challenges (i.e., patient
refusal). Tdap vaccination during pregnancy was a lower clinical priority for
some physicians. Physicians recognized the beneﬁts associated with Tdap
vaccination during pregnancy.
Conclusions: Findings indicate while most ob-gyns recognize the beneﬁts of Tdap
and recommend vaccination during pregnancy, barriers such as insurance
reimbursement and ﬁnancial concerns for the practice can outweigh the perceived
beneﬁts. This resulted in some ob-gyns reporting choosing not to stock and
administer the vaccine in their practice. Recommendations to address these
concerns include 1) structural support for Tdap vaccine administration in ob-gyns
practices; 2) Continuing medical education-equivalent educational interventions
that address management techniques, vaccine coding, and other relevant
information; and 3) interventions to assist physicians in communicating the
importance of Tdap vaccination during pregnancy.
Keywords: Infectious disease, Public health, Medicine
1. Introduction
Pertussis, or “whooping cough,” is one of the most common vaccine-preventable ill-
nesses that remain endemic throughout the world [1]. While pertussis is dangerous
for anyone that contracts it, infants are highly susceptible to developing complica-
tions from the disease [1]. In 2014, the rate of pertussis among infants <6 months
was 150.9 per 100,000 [2]. In an eﬀort to decrease pertussis morbidity and mortality,
the Advisory Committee on Immunization Practices (ACIP) has released several rec-
ommendations over the years regarding the Tdap (tetanus, diphtheria, and acellular
pertussis) vaccine for pregnant women. One of the ﬁrst strategies was implemented
in 2006, when ACIP recommended the use of “cocooning” [3]. or vaccinating all
who may come in close contact with infants. This approach proved to be logistically
challenging and insuﬃcient when used alone to prevent neonatal pertussis infections
for a variety of reasons. Most importantly, cocooning leaves vulnerable newborns
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without any endogenous protective antibodies until they begin their own vaccine se-
ries at 2 months of age, requiring the newborn to be solely dependent on the immu-
nity of those around them for the ﬁrst 2e3 months of their life [4].
Previous recommendations have also included postpartum Tdap immunization
administration [3]. In June 2011, ACIP recommended Tdap vaccination during preg-
nancy for previously unvaccinated women. The aim of this practice was to confer
maternal antibodies to the fetus in order to provide direct protection as soon as
the baby is born, providing protection when the infant is too young to get his or
her own DTaP (diphtheria, tetanus, and acellular pertussis) vaccine series [5]. In
October 2012, ACIP recommended that the Tdap vaccine be given to women during
every pregnancy (preferably between 27e36 weeks gestation), irrespective of their
prior history in receiving the vaccine, to maximize the passive antibody transfer to
the infant [6, 7, 8]. Scientiﬁc evidence shows that Tdap vaccination at 27e36 weeks
gestation is 85% more eﬀective than postpartum vaccination in protecting infants<8
weeks of age [9, 10]. Since 2012, the guidelines have been updated again by the
ACIP and the American College of Obstetricians and Gynecologists (ACOG)
with recommendations for epidemic situations, wound management, series comple-
tion, and for management of other adolescents and adults in contact with infants who
may be vulnerable to pertussis transmission [11].
In recent studies, estimates for receipt of Tdap during pregnancy varied, ranging
from a reported 14% of publicly insured pregnant women in Michigan to a reported
82% of pregnant women delivering at a University hospital [12, 13]. With the lack of
data on Tdap vaccine receipt during pregnancy and the high morbidity and mortality
of pertussis among infants at the time of the study, further investigation on the fac-
tors that inﬂuence Tdap vaccine uptake was warranted.
Previous studies have shown that Tdap vaccine uptake among pregnant women is
likely determined by a combination of factors related to both the patient and physi-
cian, with physician recommendations having a signiﬁcant inﬂuence [14, 15, 16, 17,
18, 19]. This includes receiving counseling and educational materials from physi-
cians, positive messages regarding vaccination, and accessibility of vaccines,
including on-site administration [14]. In addition, the implementation of best prac-
tice alert systems embedded within hospital electronic medical records has also
shown dramatic improvements in patient acceptance of Tdap immunization during
prenatal care (96.8% acceptance rate) [20]. Additionally, several studies have exam-
ined patient barriers to Tdap vaccine uptake during pregnancy and these have
included concern for vaccine safety and eﬃcacy during pregnancy, lack of knowl-
edge of the risk of pertussis during pregnancy, misinformation about vaccine eﬀec-
tiveness, and issues surrounding access to care [21, 22, 23, 24].
There is limited literature on provider-focused barriers to Tdap vaccination; howev-
er, there have been a few studies around provider perceptions [25]. In one study, 95%
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of physicians reported having no concerns with vaccinating during pregnancy [26].
Ninety-two percent of physicians in this survey knew the ACIP Tdap recommenda-
tions, but only 80% reported recommending Tdap to all eligible patients and 67%
administered the vaccine in oﬃce [26]. Another study reported several reasons for
physicians not vaccinating during pregnancy, including vaccine safety concerns,
discomfort with providing vaccine counseling to patients, lack of vaccine eﬃcacy
data, low perceived incidence of pertussis and inﬂuenza in the area, and the fact
that the Tdap vaccine speciﬁcally would be given postpartum in hospitals [16]. Phy-
sicians also cited several barriers against Tdap vaccine administration, with the most
common including inadequate reimbursement, vaccine associated costs, and lack of
patient interest [14, 15]. Despite physician-focused interventions to address these
barriers, including toolkits with educational materials [19, 27], it is clear that further
research is needed to understand the reasoning behind the perceptions and practices
of physicians regarding Tdap vaccination.
2. Methods
2.1. Study design and sample
The study protocol was approved by the Westat, Centers for Disease Control and
Prevention (CDC), and Emory University Institutional Review Boards and the
study was conducted in 2014. The persons eligible for this study included ob-
gyns that oﬀered prenatal care as part of their routine practice. We aimed to re-
cruit a diverse sample of physicians from across the nation in terms of patient
composition, Tdap recommendation practices, and Tdap vaccine stocking. Half
of the interviews were conducted with ob-gyns whose patient population was at
least 50 percent Hispanic, while the remainder of participating physicians saw
fewer than 50 percent Hispanic patients. We also aimed to recruit a mix of ob-
gyns who did and did not recommend Tdap vaccination to their pregnant patients
at each pregnancy; however, nearly all recruited ob-gyns (96%; n ¼ 23) recom-
mended the vaccine during the third trimester (27e36 weeks). We also sought
a mixture of physicians who did and did not stock the Tdap vaccine in their of-
ﬁces. In our ﬁnal sample, 58 percent (n ¼ 14) of ob-gyns stocked the vaccine and
42 percent (n ¼ 10) did not. Although not part of the sampling plan, the resulting
sample was overwhelmingly male (92%, n ¼ 22); it is important to note that this
is not representative of the gender proportions among ob-gyns in the United
States. All physicians were recruited through a commercial market research
ﬁrm and were provided compensation for their time with a stipend considered
non-coercive and reasonable for physician time away from clinical and adminis-
trative duties per national IRB standards.
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2.2. Interview format
A semi-structured interviewer’s guide (Table 1) was developed in collaboration with
ob-gyn and infectious disease clinicians, health communication experts, and behav-
ioral scientists. Particular care was taken in crafting a script that facilitated a conver-
sation on provider perceptions on pertussis and Tdap vaccination, current practices,
and preferred patient-provider communication materials and strategies. Twenty-four
in-depth interviews, approximately sixty minutes each, were conducted by tele-
phone. Audio recordings of the interviews were made and transcribed verbatim.
Transcripts were uploaded to NVivo 10.0 to begin the analysis process.
2.3. Code sheet development and procedures
A detailed code sheet and coding scheme were developed to capture relevant details
from the transcripts such as perceptions of pertussis and the vaccine, current recom-
mendation practices, administration and stocking, barriers to administration, and
preferred communication materials and strategies. In this study, we speciﬁcally
asked the physicians, “Do you recommend Tdap vaccine to your pregnant patients?”
If the response was aﬃrmative, we subsequently inquired, “At what point in the
pregnancy do you recommend the Tdap vaccination?” From this line of inquiry
we were therefore able to ascertain if they recommended Tdap immunization and
we were able to determine the approximate timing of the recommendations.
Table 1. Interview guide e questions for participants.
1. Can you please tell me a little bit about you and your practice?
2. On a scale of 1e5 with 1 being not at all important and 5 being very important, what do you think of
the Tdap vaccine’s importance for women? What about the Tdap vaccine’s importance for the baby?
3. Why did you give Tdap vaccine for pregnant women an X? Why did you give it an X for the baby?
4. How eﬀective do you think the Tdap vaccine is in protecting pregnant women? What about for
protecting their baby?
5. What, if anything, have you heard about the incidence of pertussis in the last few years in the United
States?
6. Do you recommend Tdap vaccine to your pregnant patients?
7. If they recommend: About what percent of your pregnant patients would you say take your
recommendation and get the Tdap vaccine while pregnant?
8. If they recommend: Can you give me an example of how that conversation goes with patients? What
do you usually say when recommending Tdap to pregnant women?
9. Does your oﬃce typically administer the Tdap vaccine or refer patients elsewhere?
10. If they administer: Have you experienced any barriers to oﬀering the Tdap at your practice?
11. If they do not recommend Tdap: What are some of the reasons why you do not recommend the Tdap
to your pregnant patients?
12. What questions or concerns, if any, do your pregnant patients have about getting the Tdap vaccine?
13. What are some ways you communicate with your pregnant patients?
14. What information or tools do you or your staﬀ need to make a strong recommendation for your
pregnant patients to get Tdap?
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Two coders were trained on the code sheet and corresponding deﬁnitions. In the
initial coding process, these team members reviewed a small sample of printed ma-
terials and independently coded the materials in an eﬀort to establish pretest reli-
ability and reﬁne any unclear areas of the code sheet and corresponding
deﬁnitions. Once reliability was established, coders began to work with the
transcripts.
Analyses utilized the constant comparative approach within the grounded theory
process model, which employs both deductive and inductive methods to allow for
the emergence of theory [27]. The ﬁrst step in this process included deductive
methods, or structural coding, that linked text associated with questions in the inter-
view guide to organize the data [28]. Subsequent content coding leading to thematic
elicitation was derived through a process of independent review of all transcripts fol-
lowed by discussion among the research team about emergent themes. Subsequent
axial coding was conducted to evaluate relationships between categories, thereby
facilitating the emergence of thematic linkages among variables. Illustrative quotes
were selected to describe emergent themes, including major themes as well as crit-
ically important minor themes that reﬂected contrasting perspectives that presented
novel opportunities for intervention (hereafter referred to as “outliers”) [29, 30].
2.4. Intercoder reliability assessment
Random samples of transcript sections (30%) were cross-coded for reliability in two
rounds. Intercoder reliability was established by comparing the presence or absence
of codes in a subsample of text from each interview. The overall reliability was
99.3%, which is above the suggested 90% agreement level [31]. The individual codes
achieved a high level of agreement, ranging from 94.2% e 100%.
3. Results
The sample of physicians interviewed consisted of 22 males and 2 females. Half
(n ¼ 12) of the interviews were conducted with physicians who stated that their pa-
tient population was50% Hispanic, while the remainder of participating physicians
(n ¼ 12) stated that they saw <50% Hispanic patients. In general, the physicians
were experienced ob-gyns who had been practicing (post-residency) for a minimum
of 12 years. Of those interviewees who speciﬁcally noted years of practice (n ¼ 20),
the range was 12e35 years. In terms of patient volume, these physicians generally
saw between 60e150 patients per week.
3.1. Recommendation vs. administration
Physicians were asked about their current practices of recommending the vaccine to
pregnant patients, administering the vaccine on site, and referring patients to
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alternative sources. Nearly all of the ob-gyns (92%, n ¼ 22) recommended the Tdap
vaccine to their patients during weeks 27e36 of pregnancy.
I wouldn’t discuss it with a new mom, you know, at a ﬁrst OB visit, I mean there
are a lot of other things to discuss, but at twenty seven weeks, I would tell her
that the recommendation is to vaccinate all pregnant women for pertussis and
for protection of the baby
There were two outliers, in terms of their practice of Tdap vaccine recommendation.
One reported recommending the Tdap vaccine postpartum, while the other only
brought up the recommendation if the patient brought it up ﬁrst. The one who rec-
ommended the postpartum immunization relied upon previous ACIP guidance in
making the recommendation at this stage, as opposed to more recent guidelines
that indicated antepartum immunization was recommended.
Additionally, 58% (n ¼ 14) of ob-gyns stocked the vaccine and 42% (n ¼ 10) did
not. Six out of the ten physicians who did not stock the vaccine indicated that
they were not as persistent as they could be in their recommendations. One physician
stated:
We probably are little lax in recommending it is my guess. I don’t know what my
nurse practitioners do.but you know after this conversation, I’m sure going to
start recommending it more.
The most prominent reasons cited by physicians for their lack of persistence
included their oﬃce not stocking and administering the vaccine, unfamiliarity
with recommendations made by other staﬀ in their oﬃce, and the sentiment that
there were other important issues to discuss with their pregnant patients.
In terms of administering and stocking the vaccine, 8 of the 10 physicians who did
not stock the vaccine explicitly stated they did not feel that not having the vaccine on
site was a barrier for their patients. Physicians who did not administer and stock the
vaccine at their practices sent their patients to a local pharmacy or their primary care
provider to receive the Tdap vaccine.
We’ve been, we’ve been very successful in educating some primary care physi-
cians who have not been aware of the recent recommendations or just having
them be aware and having these patients come and be accommodated as new
patients to initiate vaccines ﬁrst and then carry on their care for whatever other
primary care needs they may have in the future.
3.2. Implementation challenges
Overall, the four main barriers to vaccine administration cited by physicians were
insurance reimbursement, logistics, patient refusal, and transportation barriers.
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The most common barrier to vaccine administration and stocking was insurance
reimbursement. Physicians were not willing to take the risk that a patient’s insurance
may not cover the Tdap vaccine and their practice would then have to take care of the
cost. In order to avoid this risk, 10 out of 24 physicians mentioned that they did not
administer or stock the vaccine in their practices. Additionally, 8 out of these 10 phy-
sicians mentioned that insurance reimbursement was the main reason why they did
not stock the vaccine and administer it on site.
I think the biggest issue is really reimbursement, and just the hassles of trying to,
you know, we physicians, we’re getting squeezed in every possible direction.
And, there again, I don’t really want to get in a situation where it can d the
supplier is not going to tell me, I can’t tell a supplier 50 percent of my patients
didn’t pay, they’ll say who cares, they just bill.
The other two who did not administer the vaccine felt that it was easier to send the
patient to a nearby pharmacy to receive the vaccine without any challenges. There
were also two physicians who stock and administer the vaccine on site, but also dis-
cussed insurance reimbursement as being an issue that they face currently and one
physician who knew this was a challenge for others, even though it was not for him.
Another important barrier that physicians mentioned was coordination of the logis-
tics involved in vaccine administration. This includes initiating the process if the
practice were to start administering the vaccine, as well as having an individual in
charge of ordering and stocking the vaccine for continued vaccine administration.
Patient refusal was the most common non-structural barrier to vaccine administration
and was cited as an impediment by all physicians interviewed. This issue arose
among both physicians that administered the Tdap vaccine in their practices and
those that referred patients to another source for vaccination. Physicians indicated
some of the common reasons patients tended to refuse included potential out of
pocket costs associated with getting the vaccine, concerns about the safety of vacci-
nation during pregnancy, as well as overall vaccine hesitancy.
Some physicians were asked how they responded to these patients and they all stated
that while they recommended the vaccine, ultimately it is the patient’s decision. One
physician explained:
Well, yeah I just try to explain the thought behind the whole vaccination process
like with the whole pertussis protection.and that the CDC recommended or the
ACOG recommends it, but some people are, you know, that you’re just not going
to change their mind.
Additionally, three physicians mentioned that transportation was a concern for pa-
tients going oﬀ site to receive the vaccine. Of these three, two still did not admin-
ister and stock the vaccine on site, despite knowing it was a concern.
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3.3. Low clinical priority for ob-gyns
Physicians were asked if they knew about recent outbreaks of pertussis within their
community, as well as the incidence of the disease in the United States over the past
few years. Nineteen out of the twenty-four physicians in the sample knew about
recent outbreaks across the country either through reading literature or attending
conferences. However, none of the physicians had seen a case of pertussis in their
practice and nine physicians explicitly stated that pertussis was not a prevalent
enough concern within their communities to warrant attention in their practices.
.I just don’t feel as adamant about it [vaccinating against pertussis] just
because of the relative infrequency that we’ve seen the problem arise in the
community.
Six additional physicians mentioned that Tdap vaccination was not a priority in dis-
cussions with their patients, however they did not provide reasons for this. Howev-
er, all twenty-four of the physicians interviewed did agree that pertussis was a
dangerous disease, particularly for infants. As one physician explained:
I think the main importance of the vaccine is to confer immunity, you know, in
the newborn, before they can be vaccinated, because, again, newborns are very
susceptible to pertussis and it’s potentially a lethal disease.
All twenty-four physicians stated that they were made aware of the importance of
vaccinating women during pregnancy through literature sources produced by
ACOG. Twenty-two physicians stated that they believed that the literature and rec-
ommendations were credible, while two would like more research to be done before
they are convinced of the beneﬁts of Tdap vaccination during pregnancy. In gen-
eral, physicians were familiar with the risks of pertussis and up to date on the liter-
ature on Tdap vaccination, and recent recommendations, however the responses
elicited from physicians showed that Tdap vaccination was a low clinical priority
among these ob-gyns.
3.4. Vaccine beneﬁts recognized
In addition to addressing physician perceptions of pertussis and the Tdap vaccine,
this study also aimed to elicit physicians’ understanding of the beneﬁts of giving
the vaccine during pregnancy in order to gain an overall understanding of the factors
that inﬂuenced physician recommendation and administration.
Physicians were asked to discuss how important they felt the Tdap vaccine was for
both the protection of the pregnant woman and the baby. Fifteen out of the twenty-
four physicians indicated that they felt that Tdap vaccination during pregnancy was
more important for the protection of the baby than for the protection of the mother.
While all physicians did not explain the reasoning behind their answer, one reason
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given for a higher ranking for infants was that many adults have received the Tdap
vaccine at some point in their life and still have some immunity. Seven physicians
felt that Tdap vaccination during pregnancy was equally important for the protection
of the mother and the baby. There were also two outliers that believed that the Tdap
vaccination during pregnancy was more important for the protection of the mother
than for the baby.
Of the 24 physicians, 22 reported recommending Tdap vaccination during preg-
nancy, 1 recommended it postpartum, and 1 chose to not recommend it at all unless
it was ﬁrst mentioned by the patient in which case he advocated vaccination during
pregnancy. However, with evolving recommendations over time, physicians may
not have been entirely aware of the optimal timing for immunization administration.
21 of the 22 physicians that reported recommending vaccination during pregnancy
mentioned that they understood the concept of antibody transfer and how it contrib-
uted to the eﬀectiveness of the vaccine and mentioned this concept in some capacity
to their patients. One physician, despite reporting recommending the Tdap vaccine
during pregnancy, did not completely embrace revaccinating during a subsequent
pregnancy to confer passive immunity and antibody transfer.
Additionally, physicians were also asked to discuss their beliefs regarding the eﬀec-
tiveness of the vaccine in protecting a baby after birth. This received varied re-
sponses from the sample. Twenty-three physicians felt that overall the Tdap
vaccine was eﬀective, and they believed that the lower incidence of pertussis
conﬁrmed this fact. However, there was one outlier physician who felt that there
was not enough evidence to conclude that the vaccine is beneﬁcial when adminis-
tered during pregnancy and wanted more evidence in the literature. Table 2 further
summarizes these emergent themes related to physician perceptions and practices.
4. Discussion
Preventive health behaviors, particularly vaccination, are heavily inﬂuenced by
physician recommendation [14, 16, 17]. In the case of Tdap vaccination during preg-
nancy, the recommendation made by ACIP and endorsed by ACOG is relatively
recent and, thus, all patients may not be familiar with it. Several studies have shown
that patients are more likely to receive a vaccination during pregnancy, including
Tdap, if their healthcare provider recommends it during visits and provides easy ac-
cess to it [14, 16, 32e37].
In order to understand why pertussis morbidity and mortality among infants still re-
mains high, this study aimed to elicit information from ob-gyns on their perceptions
and practices regarding pertussis and Tdap vaccine recommendation, administration,
and stocking. While the majority of physicians felt that it was their responsibility as
an ob-gyn to recommend the vaccine to their patients, the strength of their
10 https://doi.org/10.1016/j.heliyon.2018.e00636
2405-8440/ 2018 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Article Nowe00636
Table 2. Emergent Themes related to Perceptions and Practice.
Prevailing view e major theme Contrasting/outlier view e minor
theme
Recommendation
vs. administration
“I certainly understand the
recommendations and support those,
but I just don’t feel as adamant about
it just because of the relative
infrequency that we’ve seen the
problem arise”
“I think that with everything else that
we have to worry about taking care of
these patients and their unborn
children.the last thing on my mind
is this vaccine. So I really think we’re
making a huge deal out of something
that is not life threatening and earth
shattering.”
“I would start by saying that we do
not stock in our oﬃce, that doesn’t
preclude me from prescribing it,
where you can go to the pharmacy,
get the vaccine as a medical beneﬁt,
like a prescription, bring it back here
and we can give you the shot.”
“Well, usually, it’s, oh we
recommend this and we don’t have it
available in the ofﬁce, we just want
you to understand that you will be
getting it in the hospital, and if the
patient has concerns, or doesn’t want
it, I mean, they wouldn’t, you know,
state that otherwise, it’s sort of much,
hey, you’re getting this, that’s it.”
Implementation
challenges
Reimbursement Challenge:
“The reimbursement is another issue.
I don’t really like to, you know,
submit any more claims to the
insurance company for them to deny
that I already do.”
“I don’t want to set a dual standard
care where you give or take a public
assistance patient and you can’t give
them a vaccine being reimbursed but
then you’re giving them to some
people that can pay. So, my limitation
on that is the inability to get
reimbursed for, on a consistent basis.
Otherwise, I would probably push it.”
Logistical Challenge:
“.Because I’m like not the
administrator person in our oﬃce,
you know, I don’t get too involved in,
you know, but storage, you know
how long, expiration, I mean there’s
like a lot of stuﬀ that goes on I think
that, you know, is complicated.”
N/A
Transportation Challenge:
“.We actually sent the patients to
the health department to get it, which
was a little bit of an issue because
most of them, well not most of them,
but some of them depend on public
transportation and so we actually had
to ﬁgure out they were going to get
there from the building that we were
in.”
N/A
Patient Refusal Challenges:
“She just didn’t like vaccines in
general, and she didn’t think she
needed it, and she just doesn’t want
to expose her baby to anything, and
she didn’t feel she needed it.”
N/A
Low clinical
priority for ob-gyns
“Well, again, and you know babies,
newborns are susceptible to pertussis
if it’s prevalent in the community. So,
“Yeah, it’s not high. I mean we still
have herd immunity, I mean it’s, I
mean I think they’re making a big
(continued on next page)
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recommendation varied. As cited in other studies, women have recalled in approx-
imately 66% of time, discussion about pertussis vaccination with providers [33]. In
our study, however, physicians cited top-of-mind reasons such as insurance reim-
bursement, logistics, transportation challenges, and patient refusal as primary bar-
riers to Tdap vaccine administration. The largest barrier to stocking and
administering the Tdap vaccine was reimbursement.
The overall sentiment among physicians regarding pertussis was that they had heard
about recent outbreaks in some capacity, either through literature or a conference
they had attended. However, the majority of physicians had not heard of any out-
breaks in the area they practiced, nor had they seen patients with pertussis. As a
result, they did not think that the susceptibility to pertussis among their patient pop-
ulation was high, resulting in a perceived lower clinical priority. Further, the major-
ity of physicians agreed that infants were vulnerable to pertussis and the symptoms
of the disease were much more severe and potentially deadly among this age group.
This study also aimed to understand physicians’ perceptions on the action of admin-
istering the Tdap vaccine to pregnant patients. All physicians interviewed were
familiar with the most recent recommendation of giving the Tdap vaccine during
the third trimester of every pregnancy. Additionally, the majority of physicians
Table 2. (Continued )
Prevailing view e major theme Contrasting/outlier view e minor
theme
I mean, if it was prevalent, I would
probably give it a ﬁve [on a 1e5
scale], but if it’s not prevalent in the
community, then the chances of
babies getting exposed to it I think
are fairly small.”
deal out of it. I’m not, I’m not
convinced it’s a big of a problem as
they’re saying it is, but, you know, I
don’t see it.”
Vaccine beneﬁts
recognized
“I think the main importance of the
vaccine is to confer immunity, you
know, in the newborn, before they
can be vaccinated, because, again,
newborns are very susceptible to
pertussis and it’s potentially a lethal
disease.”
“If some woman got vaccinated say
two to three years ago, she probably
has some antibodies to pertussis that
are still present and therefore will be
transmitted to the baby. Now then, I
don’t understand them to be as high
as if she get revaccinated, but there’s
probably some protection still
remaining.”
“I think it’s eﬀective, and I don’t see
a lot people with pertussis, so I
assume it’s working.”
“Well, there’s studies actually in the,
in the CDC report, there’s actually a
reference to a study that indicated that
the beneﬁt if anything was a very,
very negligible or slight beneﬁt for
the patient receiving it to protect her
baby. It’s, you know, when you use
this product I would imagine you’re
using it more with the intention of
protecting the mother, not with the
intention of, of providing passive
immunity to the baby.”
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stated that they felt that the vaccine was important and eﬀective due to the transfer of
pertussis antibodies from the mother to the fetus.
Based on the results of this study, provider interventions to increase their awareness
of the importance of Tdap vaccination and address some of the structural barriers
faced by providers may help improve uptake of the vaccine during pregnancy. These
interventions would cover a range of topics including information on coding for
reimbursement, proper ways to communicate the importance of Tdap vaccination
during pregnancy, and information on pertussis and Tdap vaccination in the United
States, A recent study found lack of awareness about the need for the Tdap vaccine
during pregnancy led to non-vaccination by physicians [33]. Similarly, one of the
ﬁndings of this study was that physicians didn’t connect the potential importance
of maternal Tdap vaccination in reducing pertussis among infants, particularly in
their local area. As such, educational interventions in the form of continuing medical
education (CME) modules, educational sessions at conferences, and provider-
targeted health promotion campaigns may be beneﬁcial and should be developed
and evaluated.
There were several limitations in this study. The sample was not as diverse as orig-
inally intended, particularly regarding physician gender and years in practice. Addi-
tionally, social desirability bias was also a primary concern, as it is in any study in
which respondents are asked to report on their adherence to recommended behav-
iors. While the ﬁndings are consistent with previous surveys and studies regarding
Tdap vaccination during pregnancy, it is important to note that the study was con-
ducted shortly after the release of ACOG recommendations on Tdap immunization
for each pregnancy; the data collection also occurred prior to the development of
extensive resources and educational platforms to increase Tdap vaccination in ob-
gyn practices. Further, data were collected in 2014 and provider attitudes and behav-
iors may have since changed. Finally, due to the qualitative nature of this study, ﬁnd-
ings are not intended to be representative of the entire population of ob-gyns in the
United States. While this study poses several limitations, it provides an understand-
ing of provider perceptions, practices, and other inﬂuential factors associated with
Tdap vaccination.
5. Conclusion
Barriers to recommending, stocking, and administering the Tdap vaccine among ob-
gyns include insurance reimbursement, oﬃce logistics, transportation challenges,
and patient refusal. Physicians did not express safety concerns with the Tdap vaccine
itself, but often did not ﬁnd it cost eﬀective or eﬃcient for their practice to stock or
administer the vaccine. Providers provide the vehicle to Tdap vaccination and, ulti-
mately, lower rates of pertussis morbidity and mortality among susceptible infants.
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As such, provider interventions on vaccine coding for reimbursement as well as in-
terventions to increase patient education and awareness would be most useful. There
are materials to help increase Tdap vaccination available for download from CDC
(www.cdc.gov/pertussis/pregnant) and ACOG (www.immunizationforwomen.
org). While this study speciﬁcally focuses on Tdap vaccination during pregnancy
as a prevention mechanism, the results can be applied more broadly in disease
prevention. Physician perceptions and practices signiﬁcantly impact disease
prevention, and it is important to address physician barriers, in addition to the
barriers of the population at risk, to get a complete picture.
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